Engineering T cells to improve cancer treatment
Synthetic IL9R signaling to rewire T cells for adoptive cell therapy of cancer
['FUNDING_R37'] · STANFORD UNIVERSITY · NIH-10915644
This study is looking at a new way to make cancer treatment better by changing T cells so they can fight solid tumors more effectively and safely, without the harsh side effects of traditional chemotherapy, which could help patients feel better while battling cancer.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-10915644 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing adoptive cell therapy (ACT) for cancer by engineering T cells to overcome challenges faced in treating solid tumors. The approach involves using a synthetic IL2 receptor that activates T cells without the need for toxic conditioning chemotherapy, which is typically required. By modifying T cells with unique signaling pathways, the study aims to improve their effectiveness and safety in targeting cancer cells. Patients may benefit from a more effective and less toxic treatment option for solid tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who are seeking innovative treatment options.
Not a fit: Patients with hematologic malignancies may not benefit from this research as it specifically targets solid tumors.
Why it matters
Potential benefit: If successful, this research could provide patients with a safer and more effective form of cancer immunotherapy.
How similar studies have performed: Other research has shown promise in engineering T cells for cancer treatment, but this specific approach using synthetic IL2 signaling is relatively novel.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KALBASI, ANUSHA — STANFORD UNIVERSITY
- Study coordinator: KALBASI, ANUSHA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.